Infectious disease tester Atlas picks up £16.9m venture capital backing


virus2_sqUK-based infectious disease testing company Atlas Genetics has raised £16.9m in Series B funding from a string of venture capital firms.

Novartis Venture Funds, Life Sciences Partners and BB Biotech Ventures were all among backers in the round, which also picked up capital from YFM Equity Partners and Johnson & Johnson Development Corp.

Atlas CEO John Clarkson said, “We have made tremendous progress in the development of the io system since the initial Series B investment in July 2011 and we look forward to gaining regulatory approval for our first product, a Chlamydia test, around the end of this year.”

In February 2012 Chinese venture capital firm Decheng Capital led a $12m financing round in infectious disease detection specialist GeneWeave Biosciences.

Existing investors Claremont Creek Ventures and X/Seed Capital also joined in the Series A round.

Copyright © 2014 AltAssets